Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases

Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms

(2015) Cheryl M. Koh et al.   Oncotarget

Targeting epigenetic regulators for cancer therapy

(2014) Susan Wee et al.   Annals of the New York Academy of Sciences

Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors

(2014) Kodappully Sivaraman Siveen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Epigenetics and Oncology

(2014) Padmaja Mummaneni et al.   PHARMACOTHERAPY

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity

(2013) J. Yan et al.   BLOOD

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

(2013) H. Horn et al.   BLOOD

Linking JNK-STAT3-Akt signaling axis to EZH2 phosphorylation

(2013) Yon Rojanasakul   CELL CYCLE

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

(2013) Shivani Garapaty-Rao et al.   CHEMISTRY & BIOLOGY

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity

(2013) X Zhao et al.   LEUKEMIA

Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas

(2012) Xinwei Zhang et al.   CANCER CELL

A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia

(2012) C. Simon et al.   GENES & DEVELOPMENT

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia

(2012) Panagiotis Ntziachristos et al.   NATURE MEDICINE

Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas

(2012) Michael J. Kluk et al.   PLoS One

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

(2012) W. Qi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic prospects for epigenetic modulation

(2011) Tom D Heightman   EXPERT OPINION ON THERAPEUTIC TARGETS

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling

(2010) Siok-Bian Ng et al.   JOURNAL OF PATHOLOGY

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

(2008) S. Sander et al.   BLOOD

MYCtranslocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type

(2008) S O Yoon et al.   HISTOPATHOLOGY